GlaxoSmithKline Initiates Head-to-Head Study of Cervical Cancer Vaccines
Philadelphia, Pennsylvania (ots/PRNewswire) - - Study to Compare Immunogencity of GSK's Cervical Cancer Candidate Vaccine, CERVARIX(R), to Merck's Gardasil(R) GlaxoSmithKline (NYSE: GSK) announced today the initiation of the first study of its kind designed to compare the immunogenicity of its cervical cancer candidate vaccine, CERVARIX(R), versus ...
mehr